BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li H, Xu K, Pian G, Sun S. Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth. Oncol Lett 2019;18:4735-43. [PMID: 31611983 DOI: 10.3892/ol.2019.10810] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Farmanpour-Kalalagh K, Beyraghdar Kashkooli A, Babaei A, Rezaei A, van der Krol AR. Artemisinins in Combating Viral Infections Like SARS-CoV-2, Inflammation and Cancers and Options to Meet Increased Global Demand. Front Plant Sci 2022;13:780257. [PMID: 35197994 DOI: 10.3389/fpls.2022.780257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
2 Vakhrusheva O, Erb HHH, Bräunig V, Markowitsch SD, Schupp P, Baer PC, Slade KS, Thomas A, Tsaur I, Puhr M, Culig Z, Cinatl J, Michaelis M, Efferth T, Haferkamp A, Juengel E. Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells. Front Oncol 2022;12:789284. [DOI: 10.3389/fonc.2022.789284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yang X, Zheng Y, Liu L, Huang J, Wang F, Zhang J. Progress on the study of the anticancer effects of artesunate. Oncol Lett 2021;22:750. [PMID: 34539854 DOI: 10.3892/ol.2021.13011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liao H, Shi J, Wen K, Lin J, Liu Q, Shi B, Yan Y, Xiao Z. Molecular Targets of Ferroptosis in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:985-96. [PMID: 34466409 DOI: 10.2147/JHC.S325593] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
5 Xiong Y, Huang J. Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment. Chin Med 2021;16:80. [PMID: 34407830 DOI: 10.1186/s13020-021-00489-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Chen M, Wu HL, Wong TS, Chen B, Gong RH, Wong HLX, Xiao H, Bian Z, Kwan HY. Combination of Wogonin and Artesunate Exhibits Synergistic anti-Hepatocellular Carcinoma Effect by Increasing DNA-Damage-Inducible Alpha, Tumor Necrosis Factor α and Tumor Necrosis Factor Receptor-Associated Factor 3-mediated Apoptosis. Front Pharmacol 2021;12:657080. [PMID: 34025421 DOI: 10.3389/fphar.2021.657080] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Zhang S, Mo Z, Zhang S, Li X. A Network Pharmacology Approach to Reveal the Underlying Mechanisms of Artemisia annua on the Treatment of Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2021;2021:8947304. [PMID: 33688369 DOI: 10.1155/2021/8947304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zhao F, Vakhrusheva O, Markowitsch SD, Slade KS, Tsaur I, Cinatl J Jr, Michaelis M, Efferth T, Haferkamp A, Juengel E. Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction. Cells 2020;9:E2643. [PMID: 33316936 DOI: 10.3390/cells9122643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
9 Augustin Y, Staines HM, Krishna S. Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing. Pharmacol Ther 2020;216:107706. [PMID: 33075360 DOI: 10.1016/j.pharmthera.2020.107706] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
10 Salimi A, Saboji M, Seydi E. Synergistic Effects of Ellagic Acid and Sorafenib on Hepatocytes and Mitochondria Isolated from a Hepatocellular Carcinoma Rat Model. Nutrition and Cancer. [DOI: 10.1080/01635581.2020.1829653] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Wang X, Gupta P, Jramne Y, Danilenko M, Liu D, Studzinski GP. Carnosic acid increases sorafenib-induced inhibition of ERK1/2 and STAT3 signaling which contributes to reduced cell proliferation and survival of hepatocellular carcinoma cells. Oncotarget 2020;11:3129-43. [PMID: 32913557 DOI: 10.18632/oncotarget.27687] [Reference Citation Analysis]
12 Misra R, Patra B, Varadharaj S, Verma RS. Establishing the promising role of novel combination of triple therapeutics delivery using polymeric nanoparticles for Triple negative breast cancer therapy. Bioimpacts 2021;11:199-207. [PMID: 34336608 DOI: 10.34172/bi.2021.27] [Cited by in F6Publishing: 4] [Reference Citation Analysis]